These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 30928962)
41. Causality and preventability assessment of adverse drug reactions and adverse drug events of antibiotics among hospitalized patients: A multicenter, cross-sectional study in Lahore, Pakistan. Iftikhar S; Sarwar MR; Saqib A; Sarfraz M PLoS One; 2018; 13(6):e0199456. PubMed ID: 29949616 [TBL] [Abstract][Full Text] [Related]
42. Adverse drug reactions and outcome of elderly patients on antituberculosis chemotherapy with and without rifampicin. Chan CH; Or KK; Cheung W; Woo J J Med; 1995; 26(1-2):43-52. PubMed ID: 7561530 [TBL] [Abstract][Full Text] [Related]
43. Risk assessment of hepatotoxicity among tuberculosis and human immunodeficiency virus/AIDS-coinfected patients under tuberculosis treatment. Ngouleun W; Biapa Nya PC; Pieme AC; Telefo PB Int J Mycobacteriol; 2016 Dec; 5(4):482-488. PubMed ID: 27931691 [TBL] [Abstract][Full Text] [Related]
44. [Clinical characteristics and therapeutic effect of drug-resistant tuberculosis in children]. Liao Q; Tan S; Zhu Y; Wan CM; Deng SY; Shu M Zhonghua Er Ke Za Zhi; 2017 Feb; 55(2):100-103. PubMed ID: 28173646 [No Abstract] [Full Text] [Related]
45. Discordance between patient and clinician reports of adverse reactions to MDR-TB treatment. Kelly AM; Smith B; Luo Z; Given B; Wehrwein T; Master I; Farley JE Int J Tuberc Lung Dis; 2016 Apr; 20(4):442-7. PubMed ID: 26970151 [TBL] [Abstract][Full Text] [Related]
46. Drug safety in hospitalized patients with tuberculosis: Drug interactions and adverse drug effects. Noor S; Ismail M; Khan F Clin Respir J; 2021 Jan; 15(1):97-108. PubMed ID: 32949069 [TBL] [Abstract][Full Text] [Related]
47. Drug lymphocyte stimulation test in the diagnosis of adverse reactions to antituberculosis drugs. Suzuki Y; Miwa S; Shirai M; Ohba H; Murakami M; Fujita K; Suda T; Nakamura H; Hayakawa H; Chida K Chest; 2008 Nov; 134(5):1027-1032. PubMed ID: 18583516 [TBL] [Abstract][Full Text] [Related]
48. Economic evaluation of a shortened standardised treatment regimen of antituberculosis drugs for patients with multidrug-resistant tuberculosis (STREAM): study protocol. Gama E; Madan J; Langley I; Girma M; Evans D; Rosen S; Squire SB BMJ Open; 2016 Oct; 6(10):e014386. PubMed ID: 27798041 [TBL] [Abstract][Full Text] [Related]
49. Acute biliary events during anti-tuberculosis treatment: hospital case series and a nationwide cohort study. Chang LY; Lee CH; Chang CH; Lee MC; Lee MR; Wang JY; Lee LN BMC Infect Dis; 2018 Feb; 18(1):64. PubMed ID: 29390977 [TBL] [Abstract][Full Text] [Related]
50. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial. Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149 [TBL] [Abstract][Full Text] [Related]
51. Protocol for studying cough frequency in people with pulmonary tuberculosis. Proaño A; Bravard MA; Tracey BH; López JW; Comina G; Zimic M; Coronel J; Lee GO; Caviedes L; Cabrera JL; Salas A; Ticona E; Kirwan DE; Friedland JS; Evans CA; Moore DA; Gilman RH; BMJ Open; 2016 Apr; 6(4):e010365. PubMed ID: 27105713 [TBL] [Abstract][Full Text] [Related]
52. Evaluation of risk factors associated with drug-resistant tuberculosis in Yemen: data from centres with high drug resistance. Jaber AAS; Ibrahim B BMC Infect Dis; 2019 May; 19(1):464. PubMed ID: 31126246 [TBL] [Abstract][Full Text] [Related]
53. Adverse Events in Treating Smear-Positive Tuberculosis Patients in China. Zhang T; Du J; Yin X; Xue F; Liu Y; Li R; Luo C; Li L; Li X Int J Environ Res Public Health; 2015 Dec; 13(1):. PubMed ID: 26729141 [TBL] [Abstract][Full Text] [Related]
54. [Reform of Japan's NTP and its technical perspectives]. Mori T Kekkaku; 2004 Oct; 79(10):587-604. PubMed ID: 15631111 [TBL] [Abstract][Full Text] [Related]
55. Chinese observational prospective study of ageing population with chronic kidney disease (C-OPTION): a study protocol. Liang S; Wang WL; Zhu FL; Duan SW; Sun XF; Chen XM; Cai GY; BMJ Open; 2018 Feb; 8(2):e019457. PubMed ID: 29478020 [TBL] [Abstract][Full Text] [Related]
56. Current characteristics of tuberculosis and human immunodeficiency virus co-infection in a cohort of hospitalized patients in Medellín, Colombia. Ruiz L; Maya MA; Rueda ZV; López L; Vélez LA Biomedica; 2018 Aug; 38(0):59-67. PubMed ID: 30184364 [TBL] [Abstract][Full Text] [Related]
57. Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia. Marzuki OA; Fauzi AR; Ayoub S; Kamarul Imran M Singapore Med J; 2008 Sep; 49(9):688-93. PubMed ID: 18830542 [TBL] [Abstract][Full Text] [Related]
58. Incidence of adverse drug events among patients on second line anti-tuberculosis regimen in the littoral region of cameroon. Mbuh TP; Meriki HD; Thumamo Pokam BD; Adeline W; Enoka F; Ghislain T; Mbacham WF; Ane-Anyangwe I Int J Mycobacteriol; 2021; 10(4):463-468. PubMed ID: 34916468 [TBL] [Abstract][Full Text] [Related]
59. Exploring the role of Microbiome in Susceptibility, Treatment Response and Outcome among Tuberculosis Patients from Pakistan: study protocol for a prospective cohort study (Micro-STOP). Shahzad M; Andrews SC; Ul-Haq Z BMJ Open; 2022 Jun; 12(6):e058463. PubMed ID: 35672071 [TBL] [Abstract][Full Text] [Related]
60. Global prevalence of diabetes mellitus in patients with tuberculosis: a systematic review and meta-analysis protocol. Tankeu AT; Bigna JJ; Nansseu JR; Endomba FTA; Wafeu GS; Kaze AD; Noubiap JJ BMJ Open; 2017 Jun; 7(6):e015170. PubMed ID: 28601832 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]